跳至主要内容
临床试验/IRCT20221016056190N1
IRCT20221016056190N1已完成2 期

Comparison of high-dose dual therapy and bismuth- containing quadruple therapy as a standard first line treatment in eradication of Helicobacter pylori infection

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Patients with chronic gastritis with or without improved PUD caused by Helicobacter pylori
  • Helicobacter pylori (+) determined by any of the rapid urease test and histopathology, urease breath test, fecal antigen test
  • Patients who have not received Helicobacter pylori eradication treatment

排除标准

  • Allergy to the drugs used in the study
  • Use of PPIs, H2 receptor antagonists, antibiotics, bismuth or probiotics in the last 4 weeks before entering the study
  • Smoking and alcohol abuse
  • The presence of underlying disease or conditions such as liver disease, cardiovascular disease, lung disease, metabolic disease, or malignant tumor that may affect the study
  • Pregnant or lactating female patients
  • Performing esophageal or gastric surgery procedures in the past
  • Incomplete follow-up or low acceptance capacity of patients in treatment during the study

研究者

相似试验